Trials / Completed
CompletedNCT00546624
GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine the effectiveness of MK0777 GEM versus Lorazepam in the treatment of patients with generalized anxiety disorder. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0777 |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2003-02-01
- Completion
- 2003-02-01
- First posted
- 2007-10-19
- Last updated
- 2015-11-02
Source: ClinicalTrials.gov record NCT00546624. Inclusion in this directory is not an endorsement.